Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics, Inc. asks stockholders to elect Julian Adams, Ph.D., Jay Venkatesan, M.D., and Carol Ashe to the Board for terms ending at the 2029 Annual Meeting, and to ratify Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2026. The Board recommends a vote “FOR” both proposals. The November 12, 2026 meeting will be virtual; director nominees are elected by plurality, while auditor ratification requires a majority of the voting power cast for or against.
Elicio has eight directors, six of whom the Board determined are independent. The Board has three classes with staggered three-year terms, which the company says may delay or prevent a change in management or control. As of September 17, 2026, 27,091,187 common shares were outstanding and entitled to vote; 13,545,594 shares must be represented for a quorum. Beneficial ownership figures list GKCC, LLC with 6,552,139 shares (23.2%) and Yekaterina (Katie) Chudnovsky with 9,772,764 shares (31.1%), including GKCC shares. Audit fees billed were $572,069 for 2025 and $567,800 for 2024.
Elicio Therapeutics, Inc. (ELTX) has set November 12, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location and voting matters in its future proxy statement.
Because this meeting date is more than 30 days later than the prior year’s meeting, stockholder proposals for inclusion under Rule 14a-8, as well as director nominations and other business under the company’s bylaws, must be received by the company’s Secretary at its Boston headquarters by September 24, 2026. The same September 24, 2026 deadline applies to notices required under the universal proxy rules for stockholders intending to solicit proxies for their own director nominees.
Elicio Therapeutics, Inc. (ELTX) reported that director Julian Adams received a stock option grant for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.
The award is the annual non-employee director equity grant and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to his continued service. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Carol Gail Ashe received a grant of stock options for 21,750 shares of common stock on August 31, 2026. The options have an exercise price of $2.70 per share and expire on August 31, 2036. They represent the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders meeting, subject to continued service.
Elicio Therapeutics, Inc. (ELTX) reported that director and ten percent owner Yekaterina Chudnovsky received a grant of stock options for 21,750 shares of common stock on August 31, 2026, at an exercise price of $2.70 per share, held as a direct derivative position.
The options represent her annual non-employee director equity award and will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Allen Nissenson received a stock option award for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.
The option represents the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027, or the company’s 2027 annual meeting of stockholders, provided he continues to provide services through the vesting date. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Robert R. Ruffolo received a grant of 21,750 stock options on August 31, 2026 as his annual non-employee director equity award. The options have an exercise price of $2.70 per share, cover 21,750 shares of common stock, and expire on August 31, 2036. They vest and become exercisable in full on the earlier of August 31, 2027 or the 2027 annual stockholder meeting, subject to his continued service, and no additional equity award will be made to him in connection with the 2026 annual meeting.
Elicio Therapeutics, Inc. (ELTX) reported that director Karen J. Wilson received a grant of 21,750 stock options on August 31, 2026 as an annual non-employee director equity award. The options have an exercise price of $2.70 per share, expire on August 31, 2036, and cover 21,750 shares of common stock.
The award will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to her continued service. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Jay Venkatesan received a grant of stock options for 21,750 shares of common stock on August 31, 2026 at an exercise price of $2.70 per share. The options vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to this director in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. is a clinical-stage biotech focused on AMP-based cancer immunotherapies, led by ELI-002 7P for mKRAS-positive pancreatic and other solid tumors. For the six months ended June 30, 2026, it reported a net loss of $20.0 million, slightly lower than $21.8 million a year earlier, on operating expenses of $21.0 million. Cash and cash equivalents were $23.5 million, with total assets of $31.3 million and a long-term debt balance of about $9.5 million on a $10.0 million senior secured promissory note.
The Phase 2 AMPLIFY-7P trial in adjuvant mKRAS-driven PDAC did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population, though management highlights early DFS separation during treatment, favorable safety, and stronger effects in certain subgroups to refine a planned Phase 3 strategy. Management discloses substantial doubt about the company’s ability to continue as a going concern, expecting its cash to fund operations only into the first quarter of 2027. To bolster liquidity, Elicio raised approximately $24.4 million via at-the-market equity programs in the first half of 2026 and a further $13.6 million in a July 2026 registered direct offering, but anticipates needing additional capital to advance trials and sustain operations.